N. Anthony Coles, M.D. is Founding Investor, Chairman & CEO of Yumanity Therapeutics, a Cambridge, MA-based biotechnology company focused on transforming drug discovery for neurodegenerative diseases. Previously, Coles was Chairman and CEO of Onyx Pharmaceuticals, Inc., which was acquired by Amgen in late 2013. Under his leadership, Onyx introduced two new innovative cancer medicines to patients and established the company’s international presence outside of the United States.
In March 2015, Coles was named to the National Institutes of Health (NIH) working group tasked with charting the course for President Obama’s Precision Medicine Initiative.
Coles holds a bachelor’s degree from Johns Hopkins University. Dr. Coles holds an M.D. from Duke University and a Master’s degree in Public Health from Harvard University. Dr. Coles completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School.
